1. bookVolume 75 (2021): Issue 3 (June 2021)
Journal Details
License
Format
Journal
First Published
14 Sep 2008
Publication timeframe
6 times per year
Languages
English
access type Open Access

CD63 and Dna Mismatch Repair Protein Expression in Prostate Cancer

Published Online: 22 Jul 2021
Page range: 180 - 185
Received: 02 Nov 2020
Accepted: 14 Jan 2021
Journal Details
License
Format
Journal
First Published
14 Sep 2008
Publication timeframe
6 times per year
Languages
English
Abstract

Protein expression levels in immunohistochemistry and molecular biomarkers have been reported for their ability to predict recurrence, progression, development of metastases, and patient survival. The molecular features in low- and high-grade prostate cancer can differ and influence treatment decision and prognosis. The objective of the current study was to compare the expression of exosomal biomarkers CD63 and mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) by immunohistochemistry (IHC) in tissue of patients with prostate cancer and benign hyperplasia. Altogether, 62 patients with prostate acinar adenocarcinoma and 20 patients with prostate benign hyperplasia were enrolled in this retrospective study. CD63, MSH2, MSH6, MLH1, and PMS2 expression was analysed by immunohistochemistry. The obtained results showed that CD63 expression was significantly higher in patients with Grade III–V prostate cancer compared to Grade I–II, respectively; 2.23 (1–3) vs 0.92 (0–2) score, p = 0.001. In addition, a significant positive correlation between CD63 expression and grade groups was revealed (Rho = +0.54; p < 0.0001). Furthermore, progression-free survival was significantly higher in patients with low CD63 expression, compared to high CD63 expression (p = 0.0007). MMR expression was absent in 14 patients (four patients with Grade I–II cancer and 10 patients with Grade III–cancer). MMR was present in all cases of benign prostate hyperplasia (mild to moderate staining). The conclusion was that high grade prostate cancer (Grade groups III–V) was characterised by increased CD63 expression, which correlated with progression-free survival.

Keywords

Albero-González, R., Hernández-Llodrà, S., Juanpere, N. (2019). Immunohistochemical expression of mismatch repair proteins (MSH2, MSH6, MLH1, and PMS2) in prostate cancer: Correlation with grade groups (WHO 2016) and ERG and PTEN status. Virchows Arch., 475, 223–231. Search in Google Scholar

Azmi, A. S., Bao, B., Sarkar, F. H. (2013). Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev., 32 (3–4), 623–642. Search in Google Scholar

Blume-Jensen, P., Berman, D. M., Rimm, D. L. (2015). Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin. Cancer Res., 21 (11), 2591–2600. Search in Google Scholar

Boucheix, C., Duc, G. H., Jasmin, C., Rubinstein, E. (2001) Tetraspanins and malignancy. Expert Rev. Mol. Med., 2001, 1–17. Search in Google Scholar

Brajtbord, J. S., Leapman, M. S., Cooperberg, M. R. (2017). The CAPRA score at 10 years: Contemporary perspectives and analysis of supporting studies. Eur. Urol., 71 (5), 705–709. Search in Google Scholar

Cullen, J., Rosner, I. L., Brand, T. C. (2015). A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer. Eur. Urol., 68 (1), 123–131. Search in Google Scholar

D’Amico, A. V., Whittington, R., Malkowicz, S. B. (2000). Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J. Clin. Oncol., 18 (6),1164–1172. Search in Google Scholar

Del Re, M., Biasco, E., Crucitta, S., Derosa, L., Rofi, E., Orlandini, C., Miccoli, M., Galli, L., Falcone, A., Jenster, G. W. (2017). The detection of androgen receptor splice Variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol., 71, 680–687. Search in Google Scholar

Duijvesz, D., Versluis, C. Y., van der Fels, C. A., Vredenbregt-van den Berg, M. S., Leivo, J., Peltola, M. T., Bangma, C. H., Pettersson, K. S. I., Jenster, G. (2015). Immuno-based detection of extracellular vesicles in urine as diagnostic marker for prostate cancer. Int. J. Cancer, 137, 2869–2878. Search in Google Scholar

Filella, X., Fernández-Galan, E., Bonifacio, R. F., Foj, L. (2018). Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers. Med., 11, 83–94. Search in Google Scholar

Foj, L., Ferrer, F., Serra, M., Arevalo, A., Gavagnach, M., Gimenez, N., Filella, X. (2017). Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 77, 573–583. Search in Google Scholar

Fujita, K., Nonomura, N. (2018). Urinary biomarkers of prostate cancer. Int. J. Urol., 25, 770–779. Search in Google Scholar

Guedes, L. B., Antonarakis, E. S., Schweizer, M. T. (2017). MSH2 loss in primary prostate cancer. Clin. Cancer Res., 23, 6863–6874. Search in Google Scholar

Ingrosso, G., Detti, B., Scartoni, D., Lancia, A., Giacomelli, I., Baki, M., Carta, G., Livi, L., Santoni, R. (2018). Current therapeutic options in meta-static castration-resistant prostate cancer. Semin. Oncol., 45, 303–315. Search in Google Scholar

Jahn, J. L., Giovannucci, E. L., Stampfer, M. J. (2015). The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int. J. Cancer, 137 (12), 2795–2802. Search in Google Scholar

Kharaziha, P., Chioureas, D., Rutishauser, D., Baltatzis, G., Lennartsson, L., Fonseca, P., Azimi, A., Hultenby, K., Zubarev, R., Ullen. A. (2015). Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget, 6, 21740–21754. Search in Google Scholar

Khushman, M., Bhardwaj, A., Patel, G. K., Laurini, J. A., Roveda, K., Tan, M. C., Patton, M., Singh, S., Taylor, W., Singh, A. P. (2017). Exosomal markers (CD63 and CD9) expression pattern using immunohistochemistry in resected malignant and nonmalignant pancreatic specimens. Pancreas, 46, 782–788. Search in Google Scholar

Kim, S. J., Kim, S. I. (2011). Current treatment strategies for castration-resistant prostate cancer. Korean J. Urol., 52, 157–165. Search in Google Scholar

Kretschmer, A., Tilki, D. (2017). Biomarkers in prostate cancer: Current clinical utility and future perspectives. Crit. Rev. Oncol. Hematol., 120,180–193. Search in Google Scholar

Li, G.-M. (2007). Mechanisms and functions of DNA mismatch repair. Cell Res., 18, 85–98. Search in Google Scholar

Lu, Y. T., Delijani, K., Mecum, A., Goldkorn, A. (2019). Current status of liquid biopsies for the detection and management of prostate cancer. Cancer Manag. Res., 11, 5271–5291. Search in Google Scholar

Malla, B., Aebersold, D. M., Pra, A. D. (2018). Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy. J. Transl. Med. 16, 223. Search in Google Scholar

Miki, Y., Yashiro, M., Okuno, T., Kuroda, K., Togano, S., Hirakawa, K., Ohira, M. (2018). Clinico-pathological significance of exosome marker CD63 expression on cancer cells and stromal cells in gastric cancer. PLoS One, 13 (9), e0202956. Search in Google Scholar

Moch, H., Humphrey, P. A., Ulbright, T. M., Reuter, V. E. (eds.) (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs. WHO Classification of Tumours, 4th Edition, Volume 8. WHO. 400 pp. Search in Google Scholar

Pant, S., Hilton, H., Burczynski, M. E. (2012). The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol., 83 (11), 1484–1494. Search in Google Scholar

Park, Y. H., Shin, H. W., Jung, A. R., Kwon, O. S., Choi, Y.-J., Park, J., Lee, J. Y. (2016). Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer. Sci. Rep., 6, 30386. Search in Google Scholar

Pritchard, C. C., Morrissey, C., Kumar, A. (2014) Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat. Commun., 5, 4988. Search in Google Scholar

Sharma, M., Yang, Z., Miyamoto, H. (2020). Loss of DNA mismatch repair proteins in prostate cancer. Medicine (Baltimore). 99 (19), e20124. Search in Google Scholar

Siegel, R. L., Miller, K. D., Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34. Search in Google Scholar

Soekmadji, C., Russell, P. J., Nelson, C. C. (2013). Exosomes in prostate cancer: Putting together the pieces of a puzzle. Cancers (Basel), 5 (4), 1522–1544. Search in Google Scholar

Tarhan, F., Orcun, A., Kucukercan, I., Camursoy, N., Kuyumcuoglu, U. (2005). Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology, 66, 1234–1238. Search in Google Scholar

Thompson, I. M. (2006). PSA: A biomarker for disease. A biomarker for clinical trials. How useful is it? J. Nutr., 136, 2704S. Search in Google Scholar

Wang, J. C., Louis, R., Bégin, N. G., Chevalier, B. S. Aprikian, A. G., Gourdeau, H., Chevrette, M. (2007). Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications. Clin. Cancer Res., 13 (8), 2354–2356. Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo